t
Aptamer Group plc will announce its interim results for the six months ended 31 December 2024 on Tuesday, 11 March 2025. CEO Dr Arron Tolley and CFO Andrew Rapson will provide a live investor presentation relating to these results via Investor Meet Company on the same date at 14:00 GMT. Existing and potential shareholders can submit questions until Monday, 10 March 2025, at 09:00 GMT.
| Date | 25 Feb 2025 |
| Time | 07:00:10 |
| Category | Results |
| ID | 2684Y |
25 February 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Notice of Results and Investor Presentation
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will announce its interim results for the six months ended 31 December 2024 on Tuesday, 11 March 2025.
The Company is pleased to announce that Dr Arron Tolley, Chief Executive Officer and Andrew Rapson, Chief Financial Officer, will provide a live presentation relating to the interim results via Investor Meet Company on Tuesday, 11 March 2025, at 14:00 GMT.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until Monday, 10 March 2025, 09:00 GMT, or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Aptamer Group plc via:
https://www.investormeetcompany.com/aptamer-group-plc/register-investor
Investors who already follow Aptamer Group plc on the Investor Meet Company platform will automatically be invited.
- Ends -
For further information, please contact:
|
Aptamer Group plc Arron Tolley, Chief Executive Officer |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Jade Bayat |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group plc
Aptamer Group is a leading global developer of aptamer-based ligands that help scientists remove the limits to discovery and innovation. Leveraging several proprietary discovery and development platform, Aptamer delivers custom affinity ligands, supported with a complete suite of characterisation and validatory assays that enhance the translation of its binders and optimise scientific outcomes for customers.
Aptamer's cutting-edge technology spans healthcare, research, personal care, and industrial processes, delivering new affinity solutions for novel targets, advanced diagnostics, and precision therapies. By working with industry leaders in pharmaceutical, biotechnology, personal health, academic, and clinical research sectors, Aptamer is accelerating science through the custom development of tools and therapies.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/